| New Products! |
 |
| |
|
 |
| Focus on................. |
|
| |
|
New monoclonal antibodies against human TIE-2/tek
anti-human TIE-2/tek, Clone 2, 9 and 16
(Cat# 101-M50/ -M52/ -M54).
|
Anti-Prox-1
a polyclonal antibody suitable for immunofluorescence staining of frozen sections (Cat# 102-PA32S)
|
|
FACS analysis with antibodies against Podoplanin (#101-M40) and LYVE-1 (#102-PA50)
with human microvascular endothelial cells. |
|
|
|
| Focus on....... |
|
| |
|
NEW
Anti-human
VE-Statin/EGFL-7
(cat# 102-PA14S/-14)
raised in rabbits are now available!
(Mapping/IHC/IHC2) |
NEW
Discrimination between
soluble and transmembrane Flt-1
by a specific polyclonal antibody (IHC, Cat# 102-PA21S) |
|
NEW
Two novel monoclonal antibodies that distinguish mouse lymphatic (LEC) and blood vascular (BEC) endothelial cells NOW AVAILABLE!
(Ezaki et al, 2006; Buttler et al., 2008) |
NEW
Anti-human PlGF
monoclonal antibody from mouse are now available!
(IHC with Cryo sections; Immunofluorescence) |
|
Anti-mouse/-human VEGF-A
antibodies for IHC with paraffin-embedded sections cross reacting with human tissue.
(#103-PA03S; #103-PA03AG; #101-M58)
Pretreatment: 0.01% Proteinase K, 15min, RT |
IHC with
anti-human TIE-2
monoclonal antibodies
on cryo-sections
(Figure) |
|
Anti-human CD105/Endoglin (Cat# 102-PA60)
Staining of colon carcinoma tissue (Fig.1) and FACS analysis with mouse C57B16 cells (Fig.2). |
Anti-human LYVE-1 "Biotin" (#102-PABi50) and anti-human TIE-1 Cl. 6F12 "Biotin" (#101-MBi48)
are now available for direct FACS analysis! |
|
New monoclonal antibodies against human VEGFR-2
anti-human VEGFR-2, Clone 3 and Clone 4
(Cat# 101-M32 / 101-M34). |
New monoclonal antibodies against human TIE-1
anti-human TIE-1 Clone 8C9 and 6F12
(Cat# 101-M46/ -M48) |
|
|
| New Monoclonal Antibodies! |
|
| |
|
The following monoclonal antibodies will be NOW available:
1. Mouse anti-human Podoplanin #4D5aE5E6
2. Mouse anti-rat Podoplanin #LF3(B7)D5B3
3. Mouse anti-rat Aminopeptidase P #JG12C9C10
4. Mouse anti-human Podocalyxin #GB6D9C11
5. Mouse anti-human Megalin #CD7D5
| |
|
| EU Consortium |
|
| |
|
RELIATech is a new member of the EU Consortium for Lymphangiogenomics
Since September 2007 RELIATech GmbH located in Braunschweig, North Germany, is the 14th member in the Europe-wide EU consortium „Lymphangiogenomics“ an integraded project of the “Sixth Framework Programme for Life Sciences, Genomics, and Biotechnology for Health”. Its aim is to thoroughly dissect the processes of lymphangiogenesis and to compare them with angiogenesis at the genetic, molecular, cellular, and functional level. The consortium started in 2004, is coordinated by Professor Kari Alitalo from Helsinki and was granted 9 M€. New findings and discoveries in this innovative research field should mainly lead to the development of new pharmaceuticals for the inhibition of tumor metastasis and for treatment of inflammatory and cardiovascular diseases.
For more information see: http://www.lymphomic.org/ | |
|
| Antibodies for lymphatic endothelial cells! |
|
| |
|
Cellular markers and isolation of lymphatic ECs: new possibilities for well known proteins! |
|
|
A Minireview! (More)
CD31 |
LYVE-1 |
CD31 / LYVE-1 |
The experiments were perfomed by Dr. Ulrike Fiedler and Stefanie Koidel, Dept. of Vascular Biology and Angiogenesis Research
Tumor Biology Center, Breisacher Str. 117, D-79106 Freiburg, Germany
|
|
|
|
| Antibodies for vascular endothelial cells! |
|
| |
|
VEGF receptors – key mediators of vascular formation and lymphangiogenesis |
|
|
A Minireview! (More)
| | |
|
| sVEGFR-1/sFlt-1: the exclusive Factor for Preeclampsia? |
|
| |
|
Risk from Placenta: the exclusive Factor for Preeclampsia discovered?
|
| Preeclampsia is still a very severe disease during pregnancy. The disease affected about 5% of pregnant women, about 15% of all maternal deaths are related to this disease. Up to know there is now causative treatment, - with the exception to abort pregnancy. Scientists from the Beth Israel Hospital from Boston have now identified the putative factor responsible for the disease. As recently published in the “Journal of Clinical Investigations” (Vol. 111, p. 649) it seems to be the soluble receptor protein sFlt1 (sVEGFR-1). |
|
Click here for more information | |
|
Your order »
